RxDoctor Payments Data

Alma Stacy

Family · Rockport, TXNPI 1730684168

Payments from drug & device makers

$448in general payments, 2019–2025

Across 25 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$156
  • Novo Nordisk$83
  • Bayer$52
  • Pfizer$45
  • AbbVie$40
  • Cycle Pharmaceuticals Inc$18
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC7$156
Novo Nordisk4$83
Bayer3$52
Pfizer3$45
AbbVie3$40
Cycle Pharmaceuticals Inc1$18
Shield Therapeutics Inc1$14
Vanda Pharmaceuticals Inc.1$14
Smith+Nephew1$13
AstraZeneca1$13

How this compares

$448 in reported general payments places this provider in the 50th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$123,875
Medicare patients
211
Services billed
1,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$161,950
TrulicityDulaglutide45$55,303
MounjaroTirzepatide43$50,518
MyrbetriqMirabegron37$29,293
JanuviaSitagliptin Phosphate25$27,598
JardianceEmpagliflozin26$27,276
VraylarCariprazine Hcl15$26,362
EliquisApixaban17$26,323
FarxigaDapagliflozin Propanediol22$25,239
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$23,701
RybelsusSemaglutide12$19,485
Tresiba Flextouch U-200Insulin Degludec19$13,461
SynjardyEmpagliflozin/Metformin Hcl12$13,416
TradjentaLinagliptin17$13,245
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$13,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$83$181,435146 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$13$43,35454 claims
AbbVieVraylar$40$26,36215 claims
PfizerEliquis$45$26,32317 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$156$12,54311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 15,456 family providers in Texas.

Other family in Rockport

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →